Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Lenalidomide for Relapsed/Refractory NK/T-cell Lymphoma
NCT04231370Phase 2Unknown
- Sponsor
- Beijing Tongren Hospital
- Start
- Apr 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and lenalidomide in Natural killer T-cell lymphoma (NKTL), sponsored by Beijing Tongren Hospital. Primary endpoint: Rate of Complete Response at 24 weeks. Status: unknown.
02
Drugs
sintilimablenalidomide
03
Conditions
Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT04231370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231370.